Research Article
Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia
Table 2
Antiplatelet therapy prescribed within 90 days, stratified by primary treatment modality.
| Treatment | Antiplatelet prescriptions (number) |
| Endovascular | Overall | 90 | Clopidogrel | 67 | Prasugrel | 1 | Ticagrelor | 1 | Other | 71 | Surgical | Overall | 39 | Clopidogrel | 21 | Prasugrel | 0 | Ticagrelor | 0 | Other | 33 | Amputation | Overall | 9 | Clopidogrel | 5 | Prasugrel | 0 | Ticagrelor | 0 | Other | 7 | None | Overall | 74 | Clopidogrel | 34 | Prasugrel | 0 | Ticagrelor | 0 | Other | 63 |
|
|
(i) Antiplatelet prescriptions are not mutually exclusive.
|